• Evaxion disclosed new preclinical data for its EVX-V1 cytomegalovirus vaccine program, presented today at the International Herpesvirus Workshop 2026.
• The results supported a multi-component vaccine approach, pointing to better control of infection, viral latency, and reactivation in animal studies.
• Data are expected to guide antigen selection for a future broadly protective CMV vaccine candidate, a key step toward advancing the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-004586), on July 13, 2026, and is solely responsible for the information contained therein.